U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment died ...
Meaningful use was great for the bottom line of for-profit hospitals in 2011 and Fitch Ratings expects the incentives to be larger this year and next. The firm’s quarterly diagnosis report found that ...
Feb 14 - Fitch Ratings has affirmed the ratings of Cardinal Health, Inc. (Cardinal), including the long-term Issuer Default Rating (IDR) at 'BBB+', following the announcement of the company's ...
Cardinal Health Inc. (NYSE: CAH) continues to feel the love from credit ratings agencies, with Fitch upgrading the Ohio company’s outlook to “positive.” Fitch attributed the change in Cardinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback